Australia

The Therapeutic Goods Administration (TGA) is the primary regulatory authority for health products in Australia, operating under the Therapeutic Goods Act 1989 and associated regulations including the Therapeutic Goods Regulations 1990 and the Therapeutic Goods (Medical Devices) Regulations 2002. All therapeutic goods, including pharmaceuticals, biologicals, medical devices, in-vitro diagnostics, and digital health products meeting the definition of a therapeutic good, must be entered on the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully supplied in Australia. The TGA applies a risk-based classification framework, with review pathways ranging from self-assessment and notification for lower-risk products to full pre-market evaluation for higher-risk items. Review fees, data requirements, and timelines scale with risk class and product type.

Australia requires a locally registered sponsor, which may be the manufacturer or an appointed Australian entity, to be responsible for the product throughout its lifecycle on the ARTG. The TGA broadly accepts dossiers prepared in accordance with the International Council for Harmonisation (ICH) Common Technical Document (CTD) format for pharmaceuticals and biologicals, and references the Global Harmonization Task Force (GHTF) and International Medical Device Regulators Forum (IMDRF) frameworks for medical devices. Australia participates in the Access Consortium (formerly ACSS) alongside Canada, Singapore, Switzerland, and the United Kingdom, enabling reliance pathways and parallel scientific advice for medicines and devices. Recent reforms include the TGA's ongoing International Recognition Program (IRP), formally expanded from 2023, which allows expedited assessment for products already approved by comparable overseas regulators such as the EMA, FDA, Health Canada, and MHRA, significantly reducing duplication of effort and shortening timelines for eligible applicants.

Australia operates a federated health system in which procurement responsibilities are shared between the Commonwealth (federal) government and eight state and territory governments. The Commonwealth funds the Pharmaceutical Benefits Scheme (PBS), which subsidises medicines for the general population, and the Medical Benefits Schedule (MBS), which covers medical services and some diagnostics. Listing on the PBS requires a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) following a health technology assessment (HTA) process evaluating clinical effectiveness, safety, and cost-effectiveness. For medical devices and diagnostics, the Prostheses List (PL), administered by the Department of Health and Aged Care, governs reimbursement for devices implanted in privately insured patients, while state and territory health departments conduct their own tender and formulary processes for public hospital procurement. Large-scale public hospital procurement is typically managed through state-based health procurement bodies such as Health Support Queensland, NSW Health Procurement, and equivalent agencies, often consolidating purchasing through standing offer arrangements and panel contracts.

Australia is a high-income country and is not a significant recipient of donor-funded health procurement channels such as those operated by UNICEF Supply Division, the Global Fund, USAID, or Gavi; the vast majority of health product procurement occurs through domestic public and private market mechanisms. The private sector, including private hospitals, specialist clinics, pharmacies, and pathology networks, represents a substantial parallel procurement channel operating largely through commercial wholesaler and distributor agreements. Australia does not maintain formal local manufacturing preference policies in health procurement in the same manner as some other markets; however, following supply chain disruptions experienced during the COVID-19 pandemic, the Commonwealth has introduced strategic initiatives to strengthen domestic sovereign manufacturing capability, including the National Medical Stockpile strategy and targeted investment in onshore vaccine and pharmaceutical production, which may increasingly influence procurement and contracting decisions for critical health products.